Clinical Considerations in RET Treatment and NSCLC

F

FDA Grants Regular Approval to Pralsetinib in RET Fusion-Positive NSCLC: Safety and Efficacy Update From the ARROW Trial

By Frank Griesinger 3 Videos
198 views
July 26, 2023
Comments 0
Login to view comments. Click here to Login
27:22

Targeted Therapies in Lung Cancer 2023: RET and Other Rare Fusions i…

GRACE

S. Liu

96 views
05:33

Targeted Therapies in Lung Cancer 2023: Barriers to Biomarker Testin…

GRACE

A. Desai

57 views
07:48

Intracranial Efficacy of RET Inhibitors in NSCLC

The University of Alabama at Birmingham School of Medicine

M. Khalil

78 views
11:47

ASCO® 2023 Insights: "FANSS Study - The Importance of Lung Cancer Sc…

GRACE

J. West, C. Lovly, A. Addeo

274 views
12:48

1L Treatment Options in NSCLC With Targetable Mutations

Giuseppe Lamberti

127 views
12:17

RET Fusion-Positive NSCLC

Mihaela Aldea

164 views
15:46

Targeted Therapy for RET NSCLC

2023 Texas Lung Cancer Conference Coverage

E. Santos​

83 views
21:35

Management of Advanced NSCLC: IO, Targeted Therapy, and Beyond

Total Health

T. Patil

276 views